Global equities were weaker overall last week, with developments in Europe’s fight against a second spike in COVID-19 infections outweighing more supportive newsflow. The MSCI Global Index closed the week down 0.4%, with the S&P 500 Index down 0.5%, the Stoxx Europe 600 Index down 1.4%, whilst the MSCI Asia Pacific Index outperformed, up 0.8%.1Despite headlines on Brexit, the US election, US stimulus, and the latest round of corporate earnings, there was nothing that moved the needle too much. In the absence of any market-moving news, there was some late repositioning through the week as investors bought year-to-date (YTD) underperformers. Fear was still evident in markets as volatility rose last week. Equity placings continued, with the YTD total now just short of US$100 billion globally.
COVID-19 Cases Continue to Surge
Across Europe last week, a number of countries have reported fresh highs with regards to infections. Germany, the United Kingdom, Italy, France and Spain all reported new record highs last week, bringing in fresh restrictions. Yet, whilst fatalities are on the rise too, reported deaths are still far from when they were at their peak back in spring. Nonetheless, the trajectory in the number of deaths continues to rise, and this has caused national and local leaders to tighten restrictions once again.
In the United Kingdom, we saw stricter rules implemented last week around the country. In England, where cases rose to over 35,000 per day, a new tiering systemallows the government to apply structured, localised restrictions. Swathes of northern England, including Liverpool and Manchester, were placed in “Tier 3”, which applies very restrictive controls across the hospitality and leisure sectors. Scotland, Wales and Northern Ireland also had new, more-restrictive rules introduced last week.
Germany reported a new daily infections record figure on 22 October of 11,287. Germany is widely regarded as having handled the pandemic well so the rise will be a big concern for government leaders.
Meanwhile, commentary from Spain paints a stark picture, with Prime Minister Pedro Sanchez saying on 23 October that the true number of infections in Spain was likely to be a lot higher than was being reported. Spain’s health minister also noted that “drastic” new measures were required to fight the second wave of infections. Spain has now declared a six-month state of emergency, imposing a nationwide curfew.
Elsewhere, the Czech prime minister commented that his people should brace themselves for an “enormous surge” of cases, whilst the Netherlands is expected to commence sending patients to Germany as their health care system comes under pressure.
Over the weekend, the Financial Times reported that Astrazeneca’s vaccine has induced an immune response in the elderly; however, with the official data not yet released, there is a lack of clarity around this report.2 There were also comments this morning from the UK’s Health Secretary Matt Hancock who said we should expect a vaccine rollout in the first half of 2021.
Another noisy week for Brexit, with negotiations between the European Union (EU) and the United Kingdom restarting on 29 October. Overall, things were a little more hopeful given that talks had restarted, with the pound closing the week +1% vs. the US dollar and flat vs. the euro after fading into Friday’s close. The majority of the move higher last week came on Wednesday, with hopes on the rise after it was simply announced talks would resume.
The pound did try to make another leg higher early on 23 October after headlines suggested French President Emmanuel Macron was preparing for a compromise on fisheries. The French government allegedly told the fishing industry that it would get smaller catch from UK waters from 2021. The more positive sentiment on the back of these headlines soon faded, however, with uncertainty prevailing. The latest trade talks have now been extended to the middle of this week. The United Kingdom indicated optimism that a deal would be struck with EU Chief Negotiator Michel Barnier, who was set to leave London but extending his stay until Wednesday, 28 October.
Last week, Purchasing Managers’ Index (PMI) data showed that the economic recovery in the United Kingdom lost some steam in October, with tighter restrictions clearly weighing. Manufacturing and services sectors activity both came in lower than expected, prompting further job cuts. The services sector accounts for 80% of the UK economy and is bearing the brunt of the tighter restrictions.
The United Kingdom did show some resilience vs. the eurozone in the figures, but this is likely to do with the continent seeing an earlier COVID-19 resurgence rather than anything fundamental. It’s also worth noting that the UK economy contracted more than that of any other G7 country in the first half of the year.
The defence space came under pressure last week with UK Prime Minister Boris Johnson’s three-year UK spending “master plan” set to be ditched. UK Chancellor Rishi Sunak told the Prime Minister that the comprehensive review should not go ahead amid COVID-19, dealing a blow to Johnson and his defence plans. Sunak did reveal a revised job support scheme based on the new tiered restrictions.
Week in Review
European equities underperformed their global peers last week despite staging a late rally on Friday last week. As noted, the situation on COVID-19 cases around Europe remains bleak with infection rates rising in the region. With many countries moving to stricter restrictions in recent weeks, this has naturally weighed on investor sentiment.
Again, Brexit negotiations continue to rumble on, whilst investors in Europe also keep one eye on the political picture in the United States.
The euro was stronger last week, up 1.2% vs the US dollar. Sterling was also better off, trading up 1% vs the US dollar. Rotation into some of the YTD losers set the tone for sector and broad index performance. The German DAX Index lagged on the week, down 2.0%, following some weakness in heavyweights SAP, which we have seen continue this morning, and Deutsche Telekom. The Spanish IBEX Index was the only major index to trade in the green, up 0.6%, following late strength in the banks. That strength came on the back of the rotation into some of the year’s underperformers and on the back of an earnings beat for Barclays, with the sector up 3.7% on the week.
It was the YTD outperformers which lagged through the week, with technology down 4.4% and health care down 3.2%, recording some notable weakness.
There was more of a corporate focus last week as third-quarter earnings season kicked into gear. By the end of last week, 129 Stoxx Europe 600 Index companies had reported, with just 26.5% missing estimates for the third quarter, albeit at a time of severe economic uncertainty. Earnings growth was a positive surprise, up 18%. Despite the broadly better-than-expected reports so far, many stocks have struggled to hold on to their gains. Despite the strength in the banks post-earnings, headlines later in the week suggested the European Central Bank (ECB) remains wary of allowing banks to restart dividend payments.
In terms of data, the focus was the PMIs on Friday, 23 October. The reports were a mixed bag, with the overall European Composite figure falling to 49.4. Unsurprisingly, the underperformance came from the miss in services, with the eurozone figure at 46.2. Services continue to lag with the growing restrictions on bars, restaurants, events and with many office spaces closed.
Manufacturing was strong, however, coming in at a better-than-expected 54.4. Germany mainly drove the strong manufacturing reading, helped by demand from China. What this shows to us is that there is still demand for products and services—a theme since the start of the lockdowns. As we move into the new year, hopefully we should also start to see an improvement in the services data if rates of infection are down and services resume to a reasonable capacity across Europe.
US equity markets outperformed European markets marginally, but still closed last week lower. Despite a lot of noise on the clash over the latest stimulus package and plenty of knee-jerk reactions, no real progress was made. It looks like we are unlikely to see another package until after the election, which likely weighed on markets.
Focus was firmly on US politics as the election draws closer. The final presidential debate took place on 22 October and did little to shift sentiment. Democratic nominee Joe Biden still has a high single-digit lead, according to national polls.
There was an impressive uptick in US Treasury yields last week amid expectations that a Biden win would lead to an inflationary environment given large infrastructure spending anticipated, alongside increased debt supply to finance it. The US 10-year Treasury traded above a key technical analysis indicator, its 200-day moving average, briefly for the first time since 2008, and the spread between the two-year and 10-year Treasury hit its widest level since 2018. This dynamic helped US banks, since they borrow from customers short term (deposits) vs. lending to them long term (mortgages 10-30 years). With this, the financials sector was one of the week’s winners.
As we have discussed recently, other stock winners from a Biden win would likely be the cyclicals and small/mid-capitalisation stocks given an anticipated boosted in infrastructure spending, as well as environmental, social and governance-driven (ESG) stocks (such as clean energy names) helped by Biden’s increased commitment to green infrastructure.
Whilst focus has largely fallen on the increase of COVID-19 cases throughout Europe, the United States also recorded its biggest week of new cases since the summer peak, also producing increased hospitalisations and putting strain on health care systems.
President Donald Trump continues to insist that things are fine, stating at one of his latest rallies that the United States is “rounding the turn” on the coronavirus. Vice President Mike Pence had at least four close members of his staff test positive for the virus this past weekend, but the VP himself has tested negative and will continue with planned campaign events
Despite the ongoing global increase in COVID-19 cases, optimism for a vaccine remains. Last week saw Johnson & Johnson and Astrazeneca restart US trials. Pfizer has said that it cannot request emergency authorization of its COVID-19 vaccine before the third week of November, but pictures of the production line of vaccines have now emerged, which suggests that there is some confidence.
Last week we also saw the first approval of a COVID-19-related drug as Gilead’s antiviral drug remdesivir received marketing approval from the US Food and Drug Administration (FDA).
Third-quarter earnings were another talking point, with things having gotten off to a decent start. Of companies in the S&P 500 Index reporting earnings so far, 85% have beaten expectations. Sales numbers have also been strong, with 78% of companies beating expectations. The bulk of the better-than-expected earnings have come from health care, materials, and real estate.
Asian equities traded higher overall last week, with the MSCI Asia Pacific Index closing up 0.8%. The Shanghai Composite Index lagged, down 1.7%, possibly tied to profit-taking from foreign investors. The Hang Seng Index outperformed, up 2.2%.
In terms of sector performance, there was a skew to growth as the financials were up 2.5%, industrials were up 1.5% and materials were up 1.3% last week. Defencive sectors were among the laggards, with health care down 1.6%, energy down 0.2% and consumer staples down 0.1%.
The week started with Chinese macro data. The September gross domestic product (GDP) release was a “miss” versus expectations, but still up 4.9%. Growth in industrial production and retail sales quickened, indicating that the Chinese recovery is gaining steam.
We heard from the governor of the People’s Bank of China (PBOC) last week too, who said he was confident about the prospect of a demand-driven recovery in China. China-exposed economies have benefitted too. Australia’s October PMI print came in at 54.2, illustrating the benefit of exposure to China. Meanwhile, the equivalent report for Japan, an economy more globally exposed, came in at 48.0.
Meanwhile, there were more US-imposed restrictions last week, with the US blacklisting Chinese entities and individuals who had dealt with Iran and, later in the week, the Trump administration designated some Chinese media outlets as foreign missions.
Brexit negotiations, US politics, and the ongoing pandemic will set the backdrops for markets once again. It’s also a huge week for corporate earnings; 176 companies, representing 46% of the S&P 500 Index market capitalisation will be reporting results, including the five largest companies (AAPL, MSFT, AMZN, GOOGL, FB).
Monday 26 October
Macro: US New Home Sales; German IFO Business Climate, Expectations and Current Assessment.
Tuesday 27 October
Macro: US Durable Goods Orders; Eurozone Money Supply; Chinese Industrial Profits.
Wednesday 28 October
Macro: US Wholesale Inventories; French Consumer Confidence; Japanese Retail Sales.
Thursday 29 October
Macro: US GDP, Initial Jobless Claims; Eurozone Economic Sentiment survey, Consumer Confidence; German Unemployment Claims Rate, Change in Unemployment; UK Mortgage Approvals; Japanese Industrial Production, Jobless Rate; Italian Consumer Confidence; Manufacturing Confidence.
Monetary Policy: ECB Deposit Facility Rate, PEPP purchase target; ECB’s Christine Lagarde speaks; Bank of Japan interest-rate announcement.
Friday 30 October
Macro: US Personal Income and Spending; Eurozone GDP, Unemployment Rate, consumer price index (CPI); French GDP; German GDP, Retail Sales; Spanish GDP; Italian GDP, CPI.
Views You Can Use
Insight from Our Investment Professionals
The coronavirus pandemic has created many challenges for individuals, businesses and governments around the world. In Europe, there’s a new vehicle to help finance the economic recovery there—social bonds. David Zahn, our Head of European Fixed Income, discusses this exciting new bond issuance, earmarked for funding employment initiatives. Read More.
Our Dina Ting offers three reasons she and her team believe the case for international markets is once again strong, and opines on how recent market events have created new—or amplified existing—opportunities for investors to express views on specific countries. Read More.
Given elements of uncertainty tied to COVID-19, geopolitics and policy decisions to come in the United States and across the globe, our K2 Advisors team believes the current environment may favour nimble, shorter-term strategies. Brooks Ritchey and Robert Christian provide the team’s fourth quarter hedge-fund strategy outlook. Read More.
Important Legal Information
This material is intended to be of general interest only and should not be construed as individual investment advice or a recommendation or solicitation to buy, sell or hold any security or to adopt any investment strategy. It does not constitute legal or tax advice. The views expressed are those of the team and the comments, opinions and analyses are rendered as of publication date and may change without notice. The information provided in this material is not intended as a complete analysis of every material fact regarding any country, region or market.
Companies and/or case studies referenced herein are used solely for illustrative purposes; any investment may or may not be currently held by any portfolio advised by Franklin Templeton. The information provided is not a recommendation or individual investment advice for any particular security, strategy, or investment product and is not an indication of the trading intent of any Franklin Templeton managed portfolio.
Data from third party sources may have been used in the preparation of this material and Franklin Templeton (“FT”) has not independently verified, validated or audited such data. FT accepts no liability whatsoever for any loss arising from use of this information and reliance upon the comments, opinions and analyses in the material is at the sole discretion of the user. The companies and/or case studies shown herein are used solely for illustrative purposes; any investment may or may not be currently held by any portfolio advised by Franklin Templeton.
Products, services and information may not be available in all jurisdictions and are offered outside the U.S. by other FT affiliates and/or their distributors as local laws and regulation permits. Please consult your own professional adviser or Franklin Templeton institutional contact for further information on availability of products and services in your jurisdiction.
Issued in the U.S. by Franklin Templeton Distributors, Inc., One Franklin Parkway, San Mateo, California 94403-1906, (800) DIAL BEN/342-5236, franklintempleton.com—Franklin Templeton Distributors, Inc. is the principal distributor of Franklin Templeton’s U.S. registered products, which are not FDIC insured; may lose value; and are not bank guaranteed and are available only in jurisdictions where an offer or solicitation of such products is permitted under applicable laws and regulation.
What Are the Risks?
All investments involve risk, including possible loss of principal. The value of investments can go down as well as up, and investors may not get back the full amount invested. Stock prices fluctuate, sometimes rapidly and dramatically, due to factors affecting individual companies, particular industries or sectors, or general market conditions. Bond prices generally move in the opposite direction of interest rates. Thus, as prices of bonds in an investment portfolio adjust to a rise in interest rates, the value of the portfolio may decline. Investments in foreign securities involve special risks including currency fluctuations, economic instability and political developments. Investments in developing markets involve heightened risks related to the same factors, in addition to those associated with their relatively small size and lesser liquidity.
Past performance is not an indicator or guarantee of future performance. There is no assurance that any estimate, forecast or projection will be realised.
Links to External Sites
Franklin Templeton is not responsible for the content of external websites.
The inclusion of a link to an external website should not be understood to be an endorsement of that website or the site’s owners (or their products/services).
1. Indices are unmanaged and one cannot directly invest in them. They do not include fees, expenses or sales charges. Past performance is not an indicator or a guarantee of future results.
2. Source: The Financial Times, “Oxford Covid Vaccine Trials Offer Hope for Elderly”, 26 October, 2020.